SecBot SecBot
6-K ·Filed Oct 26, 2026

BNTX

BioNTech SE
BEARISH
Impact 5/10
Processed55m ago SEC0001776985-26-000074
Notable filing: 6-K

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000074
Document: form6-ktpamtoplineresultsb.htm0001776985-26-000074
Document: 0001776985-26-000074-index-headers.html0001776985-26-000074
Document: 0001776985-26-000074-index.html0001776985-26-000074
Document: 0001776985-26-000074.txt0001776985-26-000074
33 reports for BNTX
Performance horizon
57% Hit rate @ T+60 4 of 7 directional calls Went positive at some point 7 of 12 best @ T+20▲ +25.10%Mar 24, 2026
Filters
Rows
Reports for BNTX — sortable, filterable
TypeNow
Oct 26, 2026
today
6-K
BULLISH ★ 5/10
$86.00awaiting T+60—$88.11 (+2.46%)
Oct 26, 2026
today
6-K
BEARISH ★ 5/10
$84.52awaiting T+60—$88.11 (−4.25%)
Oct 26, 2026
today
Press Release
BEARISH ★ 6/10
$88.41awaiting T+60—$88.11 (+0.33%)
Oct 25, 2026
1d ago
Press Release
BULLISH ★ 6/10
$88.40awaiting T+60—$88.11 (−0.32%)
Oct 22, 2026
3d ago
6-K
NEUTRAL ★ 5/10
$89.67awaiting T+60—$88.11 (−1.73%)
Oct 19, 2026
6d ago
6-K
NEUTRAL ★ 4/10
$89.21awaiting T+60—$88.11 (−1.23%)
Oct 19, 2026
7d ago
Press Release
NEUTRAL ★ 4/10
$89.21awaiting T+60—$88.11 (−1.23%)
Oct 13, 2026
12d ago
6-K
BEARISH ★ 6/10
$88.66awaiting T+60—$88.11 (+0.61%)
Sep 14, 2026
5w ago
6-K
BULLISH ★ 7/10
$98.86awaiting T+60—$88.11 (−10.87%)
Sep 14, 2026
6w ago
Press Release
BULLISH ★ 7/10
$98.86awaiting T+60—$88.11 (−10.87%)
Showing 10 of 33

US Market Status

Market Closed — Opens in 2h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh BNTX Intelligence

Analysis is for subscribers only.

BioNTech and DualityBio reported topline results from the DYNASTY-Breast02 Phase 3 trial of trastuzumab pamirtecan in HR+/HER2-low metastatic breast cancer. The trial met its primary endpoint with a statistically significant but modest PFS improvement versus chemotherapy, while a higher rate of…

Subscribe for Full Access